A Phase I Combination of Pazopanib and Carboplatin in Advanced Solid Malignancies

Inclusion Criteria:

- 18 years of age or older

- Histologically confirmed advanced solid tumor type that is FDA approved for treatment
with Carboplatin.

- Life expectancy at least 12 wks

- ECOG performance status of 0-2

- Provide written informed

- Adequate organ system function

FEMALES:

- Non-childbearing potential, who has had:

- A hysterectomy

- A bilateral oophorectomy (ovariectomy)

- A bilateral tubal ligation

- Is post-menopausal

- Complete abstinence from sexual intercourse 14 days before, during and at least 21
days after the last dose of investigational product

- Oral contraceptive

- Injectable progestogen

- Implants of levonorgestrel

- Estrogenic vaginal ring

- Percutaneous contraceptive patches

- Intrauterine device (IUD) or intrauterine system (IUS) with a documented failure rate
of less than 1% per year

- Sole male partner sterilization prior to the female subject's entry - Double barrier
method: condom and an occlusive cap (diaphragm or cervical/vault caps) with a vaginal
spermicidal agent (foam/ gel/ film/cream/suppository)

- If lactating: discontinue nursing prior to the first dose, during and for 14 days
following the last dose of study drug

Exclusion Criteria:

- History or clinical evidence of central nervous system (CNS) metastases or
leptomeningeal carcinomatosis, except for individuals who have previously-treated CNS
metastases, are asymptomatic, and have had no requirement for steroids or
anti-seizure medication for 6 months prior to first dose of study drug.

- Screening with CNS imaging studies (computed tomography [CT] or magnetic resonance
imaging [MRI]) is required only if clinically indicated or if the subject has a
history of CNS metastases.

- Clinically significant gastrointestinal abnormalities that may increase the risk for
gastrointestinal bleeding including, but not limited to:

- Active peptic ulcer disease

- Known intraluminal metastatic lesion/s with risk of bleeding

- Inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease), or

- other gastrointestinal conditions with increased risk of perforation

- History of abdominal fistula, gastrointestinal perforation, or intra abdominal
abscess within 28 days prior to beginning study treatment

- Clinically significant gastrointestinal abnormalities that may affect absorption of
investigational product including, but not limited to:

- Malabsorption syndrome

- Major resection of the stomach or small bowel.

- Presence of uncontrolled infection

- Corrected QT interval (QTc) > 480 msecs using Bazett's formula

- History of any one or more of the following cardiovascular conditions within the past
6 months:

- Cardiac angioplasty or stenting

- Myocardial infarction

- Unstable angina

- Coronary artery bypass graft surgery

- Symptomatic peripheral vascular disease

- Class III or IV congestive heart failure, as defined by the New York Heart
Association (NYHA)

- Poorly controlled hypertension [defined as systolic blood pressure (SBP) of greater
than or equal to 140 mmHg or diastolic blood pressure (DBP) of greater than or equal
to 90mmHg]

Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to
study entry.

- History of cerebrovascular accident including transient ischemic attack (TIA),
pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months
Note: Subjects with recent DVT who have been treated with therapeutic
anti-coagulating agents for at least 6 weeks are eligible

- Prior major surgery or trauma within 28 days prior to first dose of study drug and/or
presence of any non-healing wound, fracture, or ulcer (procedures such as catheter
placement not considered to be major)

- Evidence of active bleeding or bleeding diathesis

- Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels

- Hemoptysis within 8 weeks of first dose of study drug

- Any serious and/or unstable pre-existing medical, psychiatric, or other condition
that could interfere with subject's safety, provision of informed consent, or
compliance with study procedures

- Treatment with any of the following anti-cancer therapies:

- Radiation therapy, surgery or tumor embolization within 14 days prior to the first
dose of pazopanib OR

- Chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal
therapy within 14 days or five half-lives of a drug (whichever is longer) prior to
the first dose of pazopanib

- Any ongoing toxicity from prior anti-cancer therapy that is greater than Grade 1
and/or that is progressing in severity, except alopecia